IP Verse

Eisai R&d Management patent opposition analysis

Get complete Patent Opposition Report for Eisai R&d Management

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Latest patents of Eisai R&d Management opposed by its competitors

Explore Eisai R&d Management's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent Number	Grant Date	Title	Total Oppositions
EP3581183	Nov 29, 2023	Tumor-Treating Pharmaceutical Composition	1
EP3263106	Oct 25, 2023	Method For Suppressing Bitterness Of Quinoline Derivative	8
EP3524595	Aug 10, 2022	High-Purity Quinoline Derivative And Method For Manufacturing Same	9
EP3265122	May 4, 2022	Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer	4
EP3338779	Jun 30, 2021	Tumor Therapeutic Agent	1

Top competitors of Eisai R&d Management

STADA ARZNEIMITTEL

GENERICS UK

ACCORD HEALTHCARE